SecBot SecBot

CTNM drug pipeline

$9.67
−1.9% 1-day · Nov 16
Next catalyst
None dated
No dated FDA catalyst on file
Typical move on FDA news
No history
No past FDA events with prices
IV rank
No data
No current options data
Rated drugs
2
1 bearish · 1 neutral
Phase 3 trials
0
0 with results posted

Drugs

soonest catalyst first
● neutral
Impact
PhasePhase 2
Time to marketAt least 4-5 years away, if successful. The Phase 2 PROPEL-IPF trial is estimated to complete in June 2028, and a Phase 3 program and regulatory filing would follow, meaning potential approval is likely in the 2030-2032 timeframe at the earliest.

PIPE-791 Updated Nov 5

What to watch

PIPE-791 is a mid-stage asset with no near-term binary catalyst; the next major event is the Phase 2 PROPEL-IPF readout estimated for mid-2028. The competitive landscape shifted significantly on October 12, 2026, when BMS's admilparant succeeded in Phase 3 for IPF, potentially becoming the first approved LPAR1 antagonist. Investors should watch for enrollment completion updates and whether Contineum can differentiate PIPE-791 on safety, dosing convenience, or CNS indications (chronic pain, MS) where BMS's compound may not compete.

Bull case
  • PIPE-791 targets a clinically validated mechanism (LPAR1 antagonism) in IPF, a disease with high unmet need affecting approximately 130,000 people in the US. The Phase 1b PET trial confirmed high brain receptor occupancy, and the Phase 1b chronic pain trial showed positive exploratory efficacy signals, supporting the drug's potential as a differentiated, once-daily oral therapy.
  • The company has a strong cash position of $244.5 million as of September 30, 2026, providing runway through mid-2029, which funds the Phase 2 program and potential expansion without near-term dilution risk.
  • Analyst consensus is Buy (6 buy, 3 hold) with a mean price target of $22.14, representing approximately 147% upside from the current $8.81 price. Multiple large institutional holders including BlackRock, Franklin Resources, and Balyasny have accumulated positions.
Bear case
  • Bristol Myers Squibb's admilparant (BMS-986278), a competing LPAR1 antagonist, succeeded in its Phase 3 ALOFT-IPF trial on October 12, 2026, meeting the primary endpoint at the 60 mg dose. BMS plans to file for regulatory approval, which could make admilparant the first approved LPAR1 antagonist for IPF and potentially limit PIPE-791's market opportunity.
  • The Phase 2 PROPEL-IPF trial is not expected to read out until approximately June 2028, meaning there is no near-term binary catalyst for the stock. The stock has already fallen from its 52-week high of $17.79 to $8.81, reflecting the lack of near-term events and competitive pressure.
  • Baird downgraded CTNM from Outperform to Neutral on October 14, 2026, and the stock dropped approximately 10% on November 5, 2026. The bull/bear evidence checklist shows a bearish net signal driven by elevated short-sale volume (z-score 2.06), analyst downgrade, insider sales via 10b5-1 plans, and several institutional exits including Baker Bros. and RA Capital.
▼ bearish
Impact
PhasePhase 2 (failed)
Time to marketUncertain. J&J is evaluating exploratory data to decide whether to continue development. With two Phase 2 failures in different indications, the program's path to approval is highly uncertain and likely several years away if development continues at all.

PIPE-307 Updated Nov 5

What to watch

Watch for J&J's decision on PIPE-307's future, which could come at any time. A termination would remove any remaining upside from milestone payments and royalties, while a decision to continue into another trial would be a modest positive surprise. The more consequential catalyst for CTNM as a whole is the ongoing Phase 2 PROPEL-IPF trial of PIPE-791 (completion expected June 2028), but that is years away.

Bull case
  • J&J licensed PIPE-307 in 2023 for $50M upfront plus $25M equity investment, with over $1B in potential milestones and tiered royalties, signaling strong pharma validation of the M1R mechanism
  • Both Phase 2 trials demonstrated acceptable safety and tolerability at both doses tested, leaving room for a different dosing regimen or patient population to be explored
  • Analyst consensus remains a Buy (6 Buy/5 Strong Buy vs 3 Hold), with a mean price target of $22.14 implying ~147% upside from the $8.97 reference price as of November 5, 2026
Bear case
  • PIPE-307 has failed to meet efficacy endpoints in two separate Phase 2 trials across two different indications (RRMS and MDD), raising fundamental questions about the M1R antagonism mechanism
  • J&J is reviewing exploratory data with no announced timeline for a decision; the program could be terminated entirely, eliminating any future milestone or royalty revenue for Contineum
  • Key institutional holders including Baker Bros. Advisors and RA Capital Management exited their positions entirely in Q2 2026, and Baird downgraded the stock to Neutral in October 2026